Studies addressing drugs evaluated the use of histamines, angiotensin converting enzyme (ACE), antiplatelet, angiotensin converting enzyme inhibitors (iACE), or angiotensin receptor blockers (ARB) in the treatment of PAD, in the prevention of cardiovascular adverse events and lower limb complications22-.27 The gene discussed is ACE; the disease is peripheral arterial disease.